Literature DB >> 14615900

Familial risk of urological cancers: data for clinical counseling.

Kari Hemminki1, Xinjun Li, Kamila Czene.   

Abstract

Familial risks for cancer are important for clinical counseling and understanding cancer etiology. The nationwide Swedish Family-Cancer Database includes all Swedes born in 1932 and later (0 to 68-year-old offspring) with their parents, totaling over 10.2 million individuals. Urological cancer cases were retrieved from the Swedish Cancer Registry up to year 2000. Standardized incidence ratios (SIR) and 95% confidence limits (CI) were calculated for age-specific familial risk in offspring by an exact proband status. The familial risks for offspring cancer were increased at all urological sites from concordant cancer in the parent and in a sibling proband. The highest SIRs by parent were for testicular and prostate cancer (4.26 and 2.45). When a sibling was affected, even kidney cancer (4.74) showed a high SIR. For kidney cancers, and also for prostate and testicular cancers, the SIRs were higher among siblings than among offspring and parents, which may indicate the involvement of recessive effects. Family members of patients with prostate cancer or von Hippel Lindau disease can expect organized clinical counseling, but family members of patients with other urological cancers are probably not counseled. Guidelines for clinical counseling or action level should be developed for all urological cancers because of the established familial risks. Urological cancers also offer a challenge to molecular geneticists attempting to identify the susceptibility genes underlying the familial clustering.

Entities:  

Mesh:

Year:  2003        PMID: 14615900     DOI: 10.1007/s00345-003-0375-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  43 in total

Review 1.  Genomic medicine--a primer.

Authors:  Alan E Guttmacher; Francis S Collins
Journal:  N Engl J Med       Date:  2002-11-07       Impact factor: 91.245

2.  American Cancer Society guidelines for the early detection of cancer.

Authors:  Robert A Smith; Vilma Cokkinides; Andrew C von Eschenbach; Bernard Levin; Carmel Cohen; Carolyn D Runowicz; Stephen Sener; Debbie Saslow; Harmon J Eyre
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

3.  A genetic register for von Hippel-Lindau disease.

Authors:  I R Maddock; A Moran; E R Maher; M D Teare; A Norman; S J Payne; R Whitehouse; C Dodd; M Lavin; N Hartley; M Super; D G Evans
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

4.  Familial papillary renal cell tumors and subsequent cancers: a nationwide epidemiological study from Sweden.

Authors:  Kamila Czene; Kari Hemminki
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

5.  Familial bladder cancer in the National Swedish Family Cancer Database.

Authors:  K Plna; K Hemminki
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

6.  Familial testicular cancer and second primary cancers in testicular cancer patients by histological type.

Authors:  C Dong; I Lönnstedt; K Hemminki
Journal:  Eur J Cancer       Date:  2001-10       Impact factor: 9.162

Review 7.  Genetic testing for cancer risk.

Authors:  B Ponder
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

8.  Kidney cancer in the Swedish Family Cancer Database: familial risks and second primary malignancies.

Authors:  Kamila Czene; Kari Hemminki
Journal:  Kidney Int       Date:  2002-05       Impact factor: 10.612

9.  The nation-wide Swedish family-cancer database--updated structure and familial rates.

Authors:  K Hemminki; X Li; K Plna; C Granström; P Vaittinen
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

10.  Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study.

Authors:  T Westergaard; J H Olsen; M Frisch; N Kroman; J W Nielsen; M Melbye
Journal:  Int J Cancer       Date:  1996-05-29       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.